publication date: Jun. 29, 2018
Issue 26 - Jun. 29, 2018
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • Senate committee proposes $2 billion raise for NIH, signaling fourth good year in a row

    When the Senate Committee on Appropriations marked up the fiscal 2019 spending bill, NIH came out ahead—$2 billion ahead.

  • NCI Director’s Report

    What NCI did with the money: Sharpless boosts funding for RPGs, centers, SPOREs, NCTN, and NCORP

    In addition to a $147 million increase to the Research Grant Project pool, NCI has added $60 million to targeted research opportunities and a $20 million increase for centers and SPOREs, and $10 million for the National Clinical Trials Network and the NCI Community Oncology Research Program.

  • Turkish oncologist Murat Tuncer jailed

    A. Murat Tuncer, a pediatric oncologist and former rector of Hacettepe University, has spent the past two months in a very uncomfortable place—the Sincan Prison in Ankara.

  • In Brief

    • Case Comprehensive Cancer Center earns “exceptional” rating, $31.9M in NCI grants
    • UPMC to advise cancer treatment center in Beijing
    • UPMC and Pitt open genome center for precision medicine, immunotherapy
    • MSKCC expands its presence in Northern New Jersey
  • TCCL Logo

  • Clinical Roundup

    • Lynparza delays disease progression in phase III trial in first-line ovarian cancer
    • Tecentriq + chemo increase OS, PFS in untreated extensive stage small cell lung cancer
    • Trifluridine and tipiracil meet OS endpoint in phase III trial
    • ONS develops hazardous drugs safe handling toolkit for oncology nurses
  • Drugs & Targets

    • FDA approves Braftovi + Mektovi combination in a melanoma indication
    • Kymab, Roche agree to evaluate KY1044, anti-PD-L1 immunotherapy in solid tumors
    • FDA grants orphan drug designation for CPI-613 for Burkitt lymphoma
  • CTEP Protocol

    NCI Trials for June

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

    For further information, contact the principal investigator listed.

Copyright (c) 2018 The Cancer Letter Inc.